Acute otitis media (AOM) is a very common and usually self-limiting infection in children. Watchful waiting strategy should be discussed with parents and follow-up after 48-72 hours is arranged, if symptoms persist.

What is known about prescribing antibiotics:

What is known about prescribing antibiotics:

What is known about prescribing antibiotics:

References:

  • Del Castillo-Aguas G, et al. Acute otitis media management: A survey of European primary care pediatricians. Global Pediatrics 2023; 4 100057. https://doi.org/10.1016/j.gpeds.2023.100057

  • Le Saux N, et al. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Management of acute otitis media in children six months of age and older. Paediatr Child Health. 2016; 21(1):39-50. PMID: 26941560

  • Lieberthal AS, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013; 131(3):e964-999. PMID: 23439909 Marchisio P, et al. Italian panel for the management of acute otitis media in children. Updated guidelines for the management of acute otitis media in children by the

  • NICE guidelines 2022. Otitis media (acute): antimicrobial prescribing. https://www.nice.org.uk/guidance/ng91

  • Suzuki HG, et al. Clinical practice guidelines for acute otitis media in children: a systematic review and appraisal of European national guidelines. BMJ Open. 2020; 10(5):e035343. PMID: 32371515

  • Thomas JP, et al. Acute otitis media–a structured approach. Dtsch Arztebl Int. 2014; 28;111(9):151-9; PMID: 24661591

  • Venekamp RP, et al. Antibiotics for acute otitis media in children. Cochrane Database of Systematic Reviews 2023, Issue 11. Art. No.: CD000219. PMID: 37965923
""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative:

Your Enquiries Are Welcome

We will respond to you by Email